Résultats de la recherche
10
Tout
Rechercher les filtres
Organisation
Abpro Corporation
Abpro Announces Oral Presentation of First Preclinical Data for ABP-102/CT-P72, a Tetravalent Bispecific HER2 x CD3 T-Cell Engager, at AACR Annual Meeting 2025
25 mars 2025 16h30 HE
|
Abpro Corporation
WOBURN, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and...
Abpro Statement on the Departure of Former CEO Ian Chan
10 mars 2025 18h34 HE
|
Abpro Corporation
WOBURN, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and...
Abpro Holdings Celebrates Closing of Business Combination with Nasdaq Bell Ringing
12 déc. 2024 16h05 HE
|
Abpro Corporation
Business combination closed November 13, 2024Raised $10 million of gross proceeds in connection with the business combinationAgreements are in place with Yorkville for up to a $50 million standby...
Abpro, Atlantic Coastal Acquisition Corp. II과의 사업 결합 계약과 관련해 S-4 양식의 증권 신고서 제출 발표
22 janv. 2024 12h51 HE
|
Abpro Corporation
매사추세츠주 우번 & 뉴욕, Jan. 23, 2024 (GLOBE NEWSWIRE) -- 차세대 항체 치료제를 통해 치명적인 중증 질환에 직면한 인류의 삶을 개선해 나간다는 사명을 갖고 있는 Abpro Corporation (이하 "Abpro")와 특수목적 인수기업인 Atlantic Coastal Acquisition Corp. II (나스닥:...
Abpro Announces Filing of Registration Statement on Form S-4 in Connection with Business Combination Agreement with Atlantic Coastal Acquisition Corp. II
22 janv. 2024 08h00 HE
|
Abpro Corporation
WOBURN, Mass. and NEW YORK, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Abpro Corporation (“Abpro”), a biotech company with the mission of improving the lives of mankind facing severe and life-threatening...
Abpro Reports Its ABP 310 COVID Antibody Retains Neutralization Activity Against the SARS-CoV-2 Omicron Variant
09 déc. 2021 08h00 HE
|
Abpro Corporation
Preclinical pseudovirus data and structural modeling shows ABP 310 retains activity and potency against the SARS-CoV-2 Omicron variant mutationsABP 310 EUA possible as early as 2022 WOBURN, Mass.,...
Abpro Announces Presentation and Data at the 2021 Annual Association for Research in Vision and Ophthalmology of ABP201 for the Treatment of Wet Age-related Macular Degeneration
04 mai 2021 08h00 HE
|
Abpro Corporation
Data showed reduction of neovascular lesion formation and vascular leakage in a rodent model of choroidal neovascularizationABP201 performed equally or better than aflibercept in lesion inhibition and...
Abpro Announces Positive Phase 1 Results Demonstrating A Favorable Safety and Pharmacokinetic Profile of ABP 300, A Neutralizing Antibody Therapeutic for the Treatment of COVID-19
02 févr. 2021 08h00 HE
|
Abpro Corporation
• Results of this study showed safety and pharmacokinetic data at doses from 4 mg/kg to 60 mg/kg • Phase 2/3 registrational studies have been initiated WOBURN, Mass., Feb. 02, 2021 (GLOBE...
Abpro Announces Initiation of Phase 2/3 Registrational Studies of its Neutralizing Antibody Therapeutic ABP 300 for the Treatment of COVID-19
16 déc. 2020 08h30 HE
|
Abpro Corporation
ABP 300 is a novel human antibody therapy that has been shown to neutralize COVID-19 in preclinical in vivo studiesPivotal/Registrational studies will assess safety, tolerability, efficacy, and...
Abpro Expands Scientific Advisory Board with the Addition of Infectious Disease Leaders
25 nov. 2020 08h00 HE
|
Abpro Corporation
WOBURN, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Abpro Corporation today announced the expansion of its scientific advisory board with additions of infectious disease drug development leaders. The...